| Assessment Status | Rapid Review Complete |
| HTA ID | 26050 |
| Drug | Iptacopan |
| Brand | Fabhalta®) |
| Indication | Iptacopan (Fabhalta®) is indicated for the treatment of adult patients with complement 3 glomerulopathy (C3G) in combination with a renin-angiotensin system (RAS) inhibitor, or in patients who are RAS-inhibitor intolerant, or for whom a RAS inhibitor is contraindicated. |
| Assessment Process | |
| Rapid review commissioned | 25/09/2026 |
| Rapid review completed | 15/10/2026 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of iptacopan (Fabhalta®) for this indication compared with the current standard of care. |